| Simultaneous identification of bacterial virulence genes by negative selection M Hensel, JE Shea, C Gleeson, MD Jones, E Dalton, DW Holden Science 269 (5222), 400-403, 1995 | 1586 | 1995 |
| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial MD Tameris, M Hatherill, BS Landry, TJ Scriba, MA Snowden, S Lockhart, ... The Lancet 381 (9871), 1021-1028, 2013 | 1185 | 2013 |
| Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium. JE Shea, M Hensel, C Gleeson, DW Holden Proceedings of the National Academy of Sciences 93 (6), 2593-2597, 1996 | 1037 | 1996 |
| Genes encoding putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2 are required for bacterial virulence and proliferation … M Hensel, JE Shea, SR Waterman, R Mundy, T Nikolaus, G Banks, ... Molecular microbiology 30 (1), 163-174, 1998 | 776 | 1998 |
| Influence of the Salmonella typhimuriumPathogenicity Island 2 Type III Secretion System on Bacterial Growth in the Mouse JE Shea, CR Beuzon, C Gleeson, R Mundy, DW Holden Infection and immunity 67 (1), 213-219, 1999 | 251 | 1999 |
| Functional analysis of ssaJ and the ssaK/U operon, 13 genes encoding components of the type III secretion apparatus of Salmonella Pathogenicity Island 2 M Hensel, JE Shea, B Raupach, D Monack, S Falkow, C Gleeson, T Kubo, ... Molecular microbiology 24 (1), 155-167, 1997 | 247 | 1997 |
| Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial P Tebas, SP Yang, JD Boyer, EL Reuschel, A Patel, A Christensen-Quick, ... EClinicalMedicine 31, 2021 | 237 | 2021 |
| Characterization of Salmonella enterica Derivatives Harboring Defined aroC and Salmonella Pathogenicity Island 2 Type III Secretion System (ssaV) Mutations … Z Hindle, SN Chatfield, J Phillimore, M Bentley, J Johnson, CA Cosgrove, ... Infection and immunity 70 (7), 3457-3467, 2002 | 222 | 2002 |
| Analysis of the boundaries of Salmonella pathogenicity island 2 and the corresponding chromosomal region of Escherichia coli K-12 M Hensel, JE Shea, AJ Bäumler, C Gleeson, F Blattner, DW Holden Journal of bacteriology 179 (4), 1105-1111, 1997 | 199 | 1997 |
| Mutations in Salmonella Pathogenicity Island 2 (SPI2) Genes Affecting Transcription of SPI1 Genes and Resistance to Antimicrobial Agents J Deiwick, T Nikolaus, JE Shea, C Gleeson, DW Holden, M Hensel Journal of bacteriology 180 (18), 4775-4780, 1998 | 171 | 1998 |
| Evaluation of Salmonella typhimuriumMutants in a Model of Experimental Gastroenteritis P Everest, J Ketley, S Hardy, G Douce, S Khan, J Shea, D Holden, ... Infection and immunity 67 (6), 2815-2821, 1999 | 103 | 1999 |
| Signature-tagged mutagenesis in the identification of virulence genes in pathogens JE Shea, JD Santangelo, RG Feldman Current opinion in microbiology 3 (5), 451-458, 2000 | 96 | 2000 |
| Attenuated Salmonella SP12 mutants as antigen carriers M Hensel, DW Holden, JE Shea US Patent 7,700,104, 2010 | 69 | 2010 |
| The budding yeast U5 snRNP Prp8 is a highly conserved protein which links RNA splicing with cell cycle progression JE Shea, JH Toyn, LH Johnston Nucleic acids research 22 (25), 5555-5564, 1994 | 63 | 1994 |
| MVA85A 020 Trial Study Team: Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial MD Tameris, M Hatherill, BS Landry, TJ Scriba, MA Snowden, S Lockhart, ... Lancet 381 (9871), 1021-1028, 2013 | 62 | 2013 |
| Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG M Tameris, H McShane, JB McClain, B Landry, S Lockhart, AKK Luabeya, ... Tuberculosis 93 (2), 143-149, 2013 | 59 | 2013 |
| Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at … MP Mammen Jr, P Tebas, J Agnes, M Giffear, KA Kraynyak, E Blackwood, ... MedRxiv, 2021.05. 07.21256652, 2021 | 48 | 2021 |
| How can mathematical models advance tuberculosis control in high HIV prevalence settings? RMGJ Houben, DW Dowdy, A Vassall, T Cohen, MP Nicol, RM Granich, ... The International journal of tuberculosis and lung disease 18 (5), 509-514, 2014 | 46 | 2014 |
| SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial KA Kraynyak, E Blackwood, J Agnes, P Tebas, M Giffear, D Amante, ... The Journal of infectious diseases 225 (11), 1923-1932, 2022 | 39 | 2022 |
| Probing the active site of mitogillin, a fungal ribotoxin R Kao, JE Shea, J Davies, DW Holden Molecular microbiology 29 (4), 1019-1027, 1998 | 35 | 1998 |
